1.

O'Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, Im K, Lira Pineda A, Wasserman SM, Češka R, Ezhov MV, Jukema JW, Jensen HK, Tokgözoğlu SL, Mach F, Huber K, Sever PS, Keech AC, Pedersen TR, Sabatine MS.  Liprotein(a), PCSK9 inhibition and cardiovascular risk.  Circulation. 2019;139(12):1483-1492. doi: 10.1161/CIRCULATIONAHA.118.037184.

 

2.

Qamar A, Giugliano RP, Keech AC, Kuder JF, Murphy SA, Kurtz CE, Wasserman SM, Sever PS, Pedersen TR, Sabatine MS.  Interindividual variation in low-density lipoprotein cholesterol level reduction with evolocumab: an analysis of FOURIER trial data.  JAMA Cardiol. 2019;4:59-63. doi: 10.1001/jamacardio.2018.4178

 

3.

Martin SS, Giugliano RP, Murphy SA Wasserman SM, Stein EA Ceska R, Lopez-Miranda J, Georgiev B, Lorenzatti AJ, Tikkanen MJ, Sever PS, Keech AC, Pedersen TR, Sabatine MC.  Comparison of low-density lipoprotein cholesterol assessment by Martin/Hopkins estimation, Friedewald estimation, and preparative ultracentrifugation. Insights from the FOURIER Trial.  JAMA Cardiol 2018 doi:10.1001/jamacardio.2018.1533

 

4.

Sabatine MC, De Ferrari GM, Giugliano RP, Huber K, Lewis BS, Ferreira J, Kuder JF, Murphy SA, Wiviott SD, Kurtz CE, Honarpour N, Keech AC, Sever PS, Pedersen TR.  Clinical benefit of evolocumab by severity and extent of coronary artery disease:  an analysis from FOURIER.   Circulation. 2018:38(8):756-766. doi: 10.1161/CIRCULATIONAHA.118.034309.

 

5.

Bohula EA, Giugliano RP, Leiter LA, Verma S, Park J-G, Sever PS, Pineda AL, Honarpour N, Wang H, Murphy SA, Keech A, Pedersen TR, Sabatine MS.  Inflammatory and cholesterol risk in the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Patients with Elevated Risk).  Circulation 2018  https://doi.org/10.1161/CIRCULATIONAHA.118.034032

 

6.

Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, Sabatine MS.  Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk). 

Circulation. 2018;137(4):338-350. doi: 10.1161/CIRCULATIONAHA.117.032235.

 

7.

Giugliano RP, Keech A, Murphy SA, Huber K, Tokgozoglu SL, Lewis BS, Ferreira J, Pineda AL, Somaratne R, Sever PS, Pedersen TR, Sabatine MS.  Clinical efficacy and safety of evolocumab in high-risk patients receiving a statin: secondary analysis of patients with low LDL cholesterol levels and in those with already receiving a maximal-potency statin in a randomized clinical trial.  JAMA Cardiol. 2017:2(12):1385-1391. doi: 10.1001/jamacardio.2017.3944.

 

8.

Sabatine MS,  Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, Murphy SA, Kuder JF,  Gouni-Berthold I, Lewis BS, Handelsman Y, Pineda AL, Honarpour N,  Keech AC, Sever PS, and Pedersen TR, on behalf of the FOURIER Investigators.  Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.  Lancet Diab & Endocrin  2017;5:941-950.

 

9.

Giugliano R, Pedersen TR, Park J-G, De Ferrari GM, Gaciong ZA,  Ceska R, Toth K, Gouni-Berthold I,  Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevsky E,  Pineda AL, Somaratne R,  Wasserman SM, Keech AC, Sever PS, Sabatine MC.  Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.  2017 Lancet pii: S0140-6736(17)32290-0. doi: 10.1016/S0140-6736(17)32290-0.

 

10.

Giugliano R, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Sever PS, Robinson JG, Honarpour N, Wasserman SM, Ott BR; for the EBBINGHAUS Investigators.  Cognitive function in a randomised trial of Evolocumab.  NEJM 2017;201:377;633-643. 

 

11.

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; for the FOURIER Steering Committee and Investigators.  Evolocumab and clinical outcomes in patients with cardiovascular disease.  NEJM 2017;376(18):1713-1722.

 

12.

Giugliano RP, Mach F, Zavitz K, Kurtz C, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Sever PS, Honarpour N, Wasserman SM, Ott BR on behalf of the EBBINGHAUS Investigators.  Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy - A cognitive study of patients enrolled in the FOURIER trial.  Clin Cardiol 2017;40(2);59-65.

 

13.

Sabatine MS, Giugliano RP, Keech A, Honarpour N, Wang H, Liu T, Wasserman SM, Scott R, Sever PS and Pedersen TR.  Rational and design of the Further cardiovascular Outcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial.    Am Heart J 2016;173:94-101.